Public health

Biomedical/pharma, Personal/public health, Public health

Belgium has strong biobanks, but many still experience the system as fragmented and hard to navigate when conducting biomedical research. Experts in Belgium are arguing that we need to treat biobanks as shared infrastructure — data-rich platforms with predictable access, sustainable funding, and governance built around patient trust.
As a sector, agrifood biotech has enormous potential to improve the sustainability, resilience, and productivity of our food systems. Yet many promising innovations still fail to reach the market, often because they are not sufficiently aligned with real-world needs or adoption barriers. The B-Trust project aims to involve end-users from the start, to help make agrifood R&D more relevant, equitable, and impactful.
On 29 January 2026, 400 Belgian healthcare stakeholders — hospital executives, policymakers, and innovators — gathered in Brussels to help shape the future of healthcare. The objective was to connect hospital needs with the innovative technologies developed by Belgian companies. Two projects were honored during the event’s Innovation Awards: Baby Detect and SIM BLOOD.
We are all familiar with global viruses: The flu shows up every year across the world, and not long ago we collectively experienced the SARS-CoV-2 pandemic. Now, a neglected tropical disease is joining this club of viruses without borders. Dengue — also known as break-bone fever — is currently one of the world’s fastest spreading viral diseases, with more than half of the global population already at risk.
In December 2025, the European Commission unveiled proposed revisions to the EU’s Medical Device Regulation (MDR) and In Vitro Diagnostic Regulation (IVDR). The changes aim to accelerate the path to market for medtech and digital health companies by making the rulebook easier to navigate without lowering the bar on patient safety. Innovators have greeted the announcement with cautious optimism.
For many years, medicine has offered doctors a clear and stable path in clinical practice. But today, rising burnout, evolving patient needs, and rapid technological change are exposing the limits of that one-track career. Increasingly, physicians are redefining their roles, blending clinical work with research, policy, entrepreneurship, and more. These emerging portfolio careers may hold the key to personal fulfillment and a more resilient workforce, in medicine and beyond.
In Antwerp, a unique cohort of volunteers is helping to solve one of the world's most urgent medical challenges: the early detection of cognitive decline. While the study is local, its implications are global — providing the long-term data needed to understand the hidden years of decline in Alzheimer's disease and other forms of dementia, to enable early diagnosis and intervention.
Recently at the Medicon Valley Alliance Summit in Copenhagen, the spotlight was on European competitiveness. In a keynote, panelists from four of Europe’s leading life sciences hubs shared their intention to establish a “Champions League” of clusters, working as a team to strengthen health innovation for Europe as a whole.
Pharmacovigilance rarely makes headlines—until something goes wrong. A missed signal or a lack of coordination can have serious consequences when dealing with drugs. In today’s globalized biopharma landscape, pharmacovigilance isn’t just a box to tick—it’s a critical safeguard for both companies and the patients they serve. So how can companies improve their project governance to keep everyone safe?
Biovia is Europe’s first industry-led One Health innovation cluster—uniting medical biotech, medtech, digital health, agtech and industrial biotech to advance human and planetary health. Katrien Lorré explains how this unified approach benefits companies by unlocking opportunities and fostering a better environment for health innovation.
Researchers are sounding the alarm – there could be as much as a spoon’s worth of plastic inside our brain. Industrial activity, tire dust, lost fishing gear, and excessive use of disposable plastics are important drivers of microplastic pollution in our environment and, ultimately, in our bodies. While the full impact on human health is still being investigated, the fact that these particles can migrate into deeper tissues of our brain, crossing the blood-brain barrier, is worrying to say the least.
Belgium’s biotech sector defied global headwinds in 2024, delivering growth and key milestones. The latest analysis compiled by KBC Securities and PMV for Biovia confirms Belgium’s leadership in European health innovation. But staying on top will demand continued resilience and strategic focus.
According to the World Health Organization (WHO) SARS-CoV-2 is experiencing a resurgence, with the risk of future outbreaks from emerging variants remaining substantial. To stay ahead of the curve, continued investment in both preventative measures and novel therapies is vital. Groundbreaking Belgian research is leading the way with high-potential compounds targeting SARS-CoV-2, offering a promising new avenue for treatment and pandemic preparedness.
Even ‘safe’ levels of antibiotics in food might fuel the next generation of superbugs. Even tiny traces of antibiotics in the meat and fish we eat could contribute to antibiotic resistance. According to research by the Institute of Tropical Medicine (ITM) in Antwerp, as little as one tenth of the amount of antibiotics currently regarded as ‘safe’ by regulators is enough to trigger resistance in bacteria. Now, the scientists are expanding their research, initially performed on wax moth larvae, to mice and humans.
Luxembourg may be one of the smallest nations in the world, at just over 2,500 square kilometers and around 670,000 inhabitants, but it packs a punch in the global life sciences ecosystem. With world-class research institutes, startup accelerators, and the country’s growing digital prowess, Luxembourg is attracting global talent and putting digital healthtech solutions front and center. So, how did the Grand Duchy establish and grow its thriving research and startup landscape, and what is the vision for the future?